Catalyst Pharmaceuticals, Inc. (CPRX) on Decifer

Decifer ranks CPRX number 69 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 20% and it turns most of its profit into real cash.
• Revenue is growing about 20% a year and profits grew 27% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• Strong returns near 20% and revenue up 20% with momentum at 16 out of 35 have no growth role to buy behind now.

The current read

The evidence on CPRX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full CPRX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.